Kilambi News
Sunday, November 22, 2026

Genome writing builds mouse model of rare human brain disease

Life Sciences Sunday, November 22, 2026 - Updated Nov 22, 2026 07:05

NYU Langone researchers inserted 78,000 bases of human DNA into mice and reproduced X-linked dystonia parkinsonism in 1.5 months instead of 30 years.

Why it matters: A general method for humanizing mice with large human DNA segments could speed treatment testing across genetic diseases that ordinary editing cannot model.

Data as of Studies published in Cell on November 19, 2026; institutional release the same day. Preclinical research, no human treatment is implied.

Researchers at NYU Langone Health have used genome writing to build a mouse model of X-linked dystonia parkinsonism, a rare adult onset neurodegenerative disease, by inserting a large stretch of human DNA into the mouse version of the TAF1 gene. The studies were published in Cell on November 19.

The disease is caused by an SVA transposon, a jumping genetic element found in humans and absent in mice, inserting itself into TAF1 and reducing production of the TAF1 protein. The team rewrote part of the mouse gene with 78,000 bases of human DNA carrying the insertion. The resulting mice reproduced the disease’s molecular and clinical hallmarks, including reduced TAF1 protein, brain cell death, holes in brain tissue and severe motor deficits, in about 1.5 months. In humans the same process takes more than 30 years, a difference the researchers attribute to protective mechanisms humans evolved against these elements and mice never needed. A companion study in the same issue found that the primary cells damaged are oligodendrocytes, the support cells that insulate neurons, rather than neurons themselves, as previously assumed.

Using a molecular tool called dCas9 to boost TAF1 expression in stem cells, the team showed the insertion’s effect on TAF1 levels could be reversed, which they say points to raising TAF1 as a possible treatment strategy. Senior author Jef Boeke, director of the Institute for Systems Genetics at NYU Langone, has spent a decade developing the genome writing technique behind the work.

This is preclinical science with no product attached, and its value is the method. Many human genetic diseases are driven by large or human specific DNA elements that conventional gene editing cannot reproduce in animals. A reliable way to write those elements into mice, and compress decades of disease into months, gives drug developers a test bed for conditions that previously had none.

Sources

  1. Inserting genetic material from humans with a rare disease recapitulates the disease in mice to speed treatment design - NYU Langone Health (PR Newswire) - 2026-11-19
  2. Genome writing inserts human X-linked disease DNA into mice - Genetic Engineering and Biotechnology News - 2026-11-20